Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of rozanolixizumab in adults with ocular myasthenia gravis
jRCT2051260103Phase 3Recruiting
- Sponsor
- UCB
- Start
- Dec 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of rozanolixizumab in myasthenia gravis (MG), sponsored by UCB. Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of treatment-emergent serious adverse events and 1 more. Planned start Dec 2026; status: recruiting.
02
Drugs
rozanolixizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCT2051260103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260103.